Combination treatment of a novel CXCR3 antagonist ACT-777991 with an anti-CD3 antibody synergistically increases persistent remission in experimental models of type 1 diabetes.

MLA

Christen, Urs, et al. “Combination Treatment of a Novel CXCR3 Antagonist ACT-777991 with an Anti-CD3 Antibody Synergistically Increases Persistent Remission in Experimental Models of Type 1 Diabetes.” Clinical & Experimental Immunology, vol. 214, no. 2, Nov. 2023, pp. 131–43. EBSCOhost, https://doi.org/10.1093/cei/uxad083.

APA

Christen, U., Pouzol, L., Tunis, M., Sassi, A., Tondello, C., Bayer, M., Hintermann, E., Strasser, D. S., Schuldes, S., Mentzel, U., & Martinic, M. M. (2023). Combination treatment of a novel CXCR3 antagonist ACT-777991 with an anti-CD3 antibody synergistically increases persistent remission in experimental models of type 1 diabetes. Clinical & Experimental Immunology, 214(2), 131–143. https://doi.org/10.1093/cei/uxad083

Chicago

Christen, Urs, Laetitia Pouzol, Mélanie Tunis, Anna Sassi, Camilla Tondello, Monika Bayer, Edith Hintermann, et al. 2023. “Combination Treatment of a Novel CXCR3 Antagonist ACT-777991 with an Anti-CD3 Antibody Synergistically Increases Persistent Remission in Experimental Models of Type 1 Diabetes.” Clinical & Experimental Immunology 214 (2): 131–43. doi:10.1093/cei/uxad083.